Regenerxbio dosed first patient in sura-vec trial for diabetic retinopathy.
Regenerxbio announced the first patient dosed in the NAAVIGATE trial and received a $100 million milestone payment from AbbVie. This milestone highlights progress in potential one-time gene therapies for diabetic retinopathy, aiming to reduce vision loss.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day